Indivior to delist on 25 July Move aligns with US market focus Shares down 35% over one year Global pharmaceutical firm Indivior (INDV) is to become the latest company to delist from the London Stock Exchange (LSE) in favour of the US market in the latest blow to Britain's embattled bourse. Headquartered across the pond in Richmond, Virginia, the opioid addiction treatment specialist will...

Decline projected for 2025 profitIncreased competition bitesMaintains medium-term sales targetOpioid addiction treatment specialist Indivior (INDV) appears to be getting into some bad habits of its own. In a full year trading update on Thursday (20 Feb), the company slashed its 2025 outlook, sending the shares spiralling down by around a fifth to 681p.This comes on top of a warning in July...

Group's move will happen over the next 12-18 monthsGroup rental revenue up 6% to $5.26 billion for first halfFull-year guidance revised downwardsShares in Ashtead (AHT) fell as much as 10% in morning trading as the equipment rental firm issued a profit warning and said it will be moving its primary listing to the US.The equipment rental firm joins a growing list of UK companies moving their...

Full year profit guidance cut by 15%130 jobs axed as schizophrenia drug droppedPeak Sublocade sales guidance reiteratedShares in Indivior (INDV) sank more than 40% to 694.5p after the opioid addiction treatment company issued a full year profit warning and announced 130 job cuts related to the discontinuation of its schizophrenia drug Perseris.The shares have been highly volatile in recent...

Opioid-use disorder treatment specialist Indivior (INDV) shot out the blocks in the early part of 2024 driven by stronger than expected full-year profit, (22 February) a strong outlook and excitement over its proposed US Nasdaq listing.Since then, the shares have lost nearly 30% of their value compared with a 6% gain in the mid-cap FTSE 250 index, making them one of the worst performers over...

Shares in Indivior (INDV) are up 36% year-to-date. The latest catalyst for the opioid-use disorder treatment specialist came in the form of 2023 sales and profit towards the top end of expectations and guidance for stronger than forecast profit growth in 2024 (22 February).Also giving the shares a boost was the news the company plans to move its primary stock exchange listing to the US where...

Full year sales and profit up 21% and 27% respectivelyPlans for primary US listing2024 outlook above consensus estimatesShares in Indivior (INDV) surged 18% to top the FTSE mid-cap index after the Opioid-use disorder treatment specialist reported full year sales and profit towards the top end and guided for stronger than expected profit growth in 2024.Also giving the shares a boost was the...

Stock prices in London were in the green at midday Thursday, as UK purchasing managers? index data indicated that the UK recession is ?already? over.Eye are now on US jobless data, which will be released at 1330 GMT.The FTSE 100 index was up 20.96 points, 0.3%, at 7,683.47. The FTSE 250 was up 135.16 points, 0.7%, at 19,254.13, and the AIM All-Share was up 0.86 of a points, 0.1%, at 750.88.The...

As we approach the end of the year it is an opportune moment to shine a light on some of this year's least-loved stocks.Rather than look at the stocks which have lost the most, we have collected together those trading at or near their lows for the year along with those with the fewest friends in the analyst community and those which the hedge fund community thinks are outright shorts.If we...

Legacy Suboxone cases settled for $385 millionCompany to book a $228 million charge in Q3Year to date sales up 21% and adjusted operating profit up 17%Leading addiction treatment company Indivior (INDV) provided good news for investors on Monday in an otherwise weak market after settling a US Multi-District Litigation case for $385 million.The trial which was due to start on 30 October will...

Indivior £15.99Loss to date: 6.8%Consistent upgrades to earnings from both the company and analysts resulting from strong growth in OUD (opioid use disorder) treatment Sublocade prompted us to turn positive on Indivior (INDV) in November 2022.We argued the shares looked too cheap against the growth potential of the business but caveated the positive narrative because of the potential for...

- Unexpected $290m charge pushes company into loss- Underlying business performing as hoped- US listing planned this SpringOpioid-use disorder treatment company Indivior (INDV) booked a $290 million exceptional provision for potential damages relating to legacy antitrust litigation cases, pushing it to a full year net loss of $183 million for 2022.The surprise news sent the shares down 11% to...

Many healthcare stocks did well on the stock market in 2022, yet one company stood out as a laggard due to a legal matter which has just seen an important breakthrough.GSK (GSK) fell 10% in the year versus a 34% gain both from AstraZeneca (AZN) and Eli Lilly (LLY:NYSE), and a 48% advance from Indivior (INDV).Holding the FTSE 100 company's shares back has been litigation pursued in US courts...

Most investors will remember 2022 as being one of the toughest years for stock markets around the world in a long time. However, plenty of stocks have delivered positive returns.In this feature we look at the best performing London-listed stocks spread across four different parts of the market, covering small, medium and large sized companies.£5 billion+ market capIreland has been one of the...

Heightened macroeconomic risks and recession worries increase the likelihood of seeing more downgrades in company earnings. This puts a premium on finding companies whose earnings are less affected by the worsening economic backdrop.One such company in our view is Indivior (INDV) which develops medicines for drug addiction and mental illnesses. The company has seen continued strong demand for...

- First half sales grow 12% to $428 million- 7% upgrade to Sublocade full year sales guidance- US listing planned for spring of 2023Global pharmaceutical company Indivior (INDV), which is focused on substance abuse disorders, said first half revenues grew 12% to $428 million while adjusted operating profit fell 10% to $117 million impacted by increased operating expenses.Management raised full...

One of the UK market's biggest corporate splits in years is about to happen, with GSK (GSK) demerging its consumer healthcare business called Haleon. The latter should become a FTSE 100 company and give investors exposure to some of the best-known brands in toothpaste, painkillers and more.This article will give you the essential details on Haleon and its prospects. But if you're still unsure...

In a rough start to 2022 for markets one stock which has bucked the general trend is pharmaceutical company Indivior (INDV), whose shares are up 30% year-to-date.In this article we uncover the reasons for recent share price strength and argue that strong earnings momentum can continue to drive the shares higher irrespective of general market weakness.A ROLLERCOASTER RIDEIndivior is a global...

We might have thought we'd seen it all after 2020 but it's been quite a year in 2021 too with an impressive rebound for the markets from the ravages of the pandemic.But which stocks have done best? Read on to discover the top performers up and down the market cap spectrum and find out why they've done so well. For the purposes of this article we've deliberately excluded investment trusts.£4...

UK stocks pulled back from their recent highs on Wednesday as first quarter GDP fell 1.6%, revised down from 1.5% reflecting the most recent lockdown, and oil prices retreated.Brent crude futures gave up 0.3% to $74 per barrel while precious metals were also weaker, with gold down 0.2% at $1,758 per ounce, capping its worst monthly performance for a couple of years, down 8% since the start of...